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ABSTRACT
Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Inter-
national Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature
on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis
type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend opti-
mal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials.
Methods: A systematic process was used to review all published data about WB-MRI in NF syn-
dromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific
techniques for assessment of tumor burden, characterization of neoplasms, and response to
therapy.
Results:WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR)
sequence is used in all investigations to date, suggesting consensus about the utility of this
sequence for detection ofWB tumor burden in people with NF. There are insufficient data to support
a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches.
Functional imaging, although used in some NF studies, has not been systematically applied or eval-
uated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI
reproducibility.
Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The
STIR sequence is a core sequence. Additional investigation is needed to define the optimal
approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic perfor-
mance of WB-MRI vs regional MRI. Neurology® 2016;87 (Suppl 1):S31–S39
GLOSSARY
ADC 5 apparent diffusion coefficient; DWI 5 diffusion-weighted imaging; FDG 5 fluorodeoxyglucose; MPR 5 multiplanar
reformation; NF1 5 neurofibromatosis type 1; NF2 5 neurofibromatosis type 2; PNST 5 peripheral nerve sheath tumors;
REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis; SNR 5 signal to noise ratio; STIR 5 short tau
inversion recovery; SWN 5 schwannomatosis; WB-MRI 5 whole-body MRI.
Whole-body MRI (WB-MRI) allows imaging of a large volume of the body in a single image
acquisition session. It has been extensively investigated for the detection and staging of visceral
and osseous tumors1–6 and is well-suited to tumor syndromes including neurofibromatosis type 1
(NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN),7–9 as these patients
often have a high burden of tumors as well as large tumors that cross anatomic planes (figure).
WB-MRI has been used to evaluate tumor burden and to characterize neoplasms in patients
with NF syndromes10–23 and is being used in some clinical trials to evaluate response to therapy
(NCT01207687). A uniform image acquisition protocol and interpretation method would
enable WB-MRI to be used as a key endpoint to assess tumor treatment response in multicenter
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clinical trials for NF-associated peripheral nerve
sheath tumors (PNST). However, thus far, vari-
able approaches have been used for WB-MRI
acquisition and image analysis in NF.
The WB-MRIWorking Group was formed
as part of the Response Evaluation in Neurofi-
bromatosis and Schwannomatosis (REiNS)
International Collaboration to generate con-
sensus recommendations and identify priority
areas for future research regarding WB-MRI as
applied to NF clinical trials. The working
group reviewed the existing literature on the
use of WB-MRI in patients with NF1, NF2,
and SWN to evaluate differences in image
acquisition (including magnet strengths, imag-
ing planes, and 2D vs 3D approaches); assess
the feasibility, reproducibility, and diagnostic
accuracy of WB-MRI in people with NF;
and evaluate the benefits of functional MRI
techniques, such as diffusion-weighted imaging
(DWI) with quantitative apparent diffusion
coefficient (ADC) maps and contrast-enhanced
imaging for NF-associated PNST. We used this
information to recommend best practices for
WB-MRI for use in NF clinical trials and to
establish research priorities for future studies.
METHODS A computer-aided search of PubMed/MEDLINE
from inception to May 2015 was conducted to find relevant
English language publications on WB-MRI and NF syndromes.
To expand our search, bibliographies of retrieved articles were
screened for additional citations. A single reviewer (S.A.)
independently screened titles, abstracts, full articles, and
references to determine eligibility for inclusion. Studies were
included if they had a prospective or retrospective study design
with patients of any age with NF1, NF2, and SWN using WB-
MRI in which at least the area from the neck to the pelvis was
imaged. Review articles, meta-analyses, abstracts, case reports, or
case series of less than 10 patients, guidelines, or studies
performed in animals were excluded.
Inclusion of patients based on well-established clinical criteria
for the NF syndromes was adequate for selection of the patient pop-
ulation, given that pathologic confirmation of each neoplasm is not
feasible.7–9 All included articles were analyzed for diagnosis (NF1,
NF2, and SWN), index test (WB-MRI), and reference test (clinical
criteria for diagnosis of the NF syndromes). The following infor-
mation was extracted from articles: author name, year of publica-
tion, number of participants, specific tumor syndrome, magnet
strength (1.5T vs 3.0T), specific WB-MRI techniques (2D vs 3D
imaging, specific imaging sequences, inclusion of functional MRI
sequences, contrast administration), sex, mean age with SD, quan-
tification of PNST size (2D vs volumetric), and types of tumors
(malignant vs benign PNST). WB-MRI studies were also classified
by clinical indication into 3 categories: tumor detection (including
extent of disease), tumor characterization, or response to therapy.
RESULTS The literature search yielded 25 articles.
After full review of the articles, 14 studies met all inclu-
sion criteria.10–23 Two studies were excluded as they
discussed extratumoral findings (i.e., incidental find-
ings onWB-MRI in NF or marrow changes in patients
with NF treated with imatinib mesylate22,23). Hence,
the final analysis included 12 studies.10–21
WB-MRI acquisition protocols. Table 1 summarizes
the information extracted from the investigations that
met inclusion criteria. Of the 12 publications, 11
employed 1.5T magnet strength10–12,14–21; only 1
study used 3.0T magnet.13 One study performed at
3.0T acquired volumetric 3D images with isotropic
resolution in the coronal plane and generated multi-
planar reformations (MPR) in sagittal and axial plane
with good diagnostic quality.13 The remainder of the
WB-MRI investigations utilized 2D acquisitions in
the coronal plane alone, or in both coronal and axial
planes. All investigations included a short tau inversion
Figure Whole-body MRI in neurofibromatosis
(A) A person with schwannomatosis. (B) A person with neurofibromatosis type 1. In both im-
ages, the range of field of view is apparent depending on the table length and the size of the
person being imaged and in both images several tumors distributed across anatomic regions
can be identified. In (B), some of the artifact that can occur affecting interpretation is
apparent.
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recovery (STIR) sequence. Only 1 trial performed
functional MRI with quantitative DWI and ADC
maps.13 DWI technique included 3 b values and was
performed with slice thickness of 5 mm.13 Three of
the 12 studies used contrast material as an adjunct to
traditionalWB-MRI fluid-sensitive sequences.11,13,14 One
study obtained postcontrast 3D volumetric gradient echo
images13 while the other study obtained 2D spin echo
T1-weighted images with fat suppression.14 In 1 study,
investigators found contrast to be useful in distinguishing
PNST from perineural cysts.13
WB-MRI applications.With respect to image interpreta-
tion and analysis, the following aspects were specifically
assessed: tumor detection (evaluation of WB tumor
burden, including tumor size), tumor characterization,
and the assessment of treatment response (table 2).
There are varied methods of WB tumor burden eval-
uation, with recent studies favoring 3D tumor volu-
metry, rather than 1D or 2D linear measurements
(such as Response Evaluation Criteria in Solid Tumors
[RECIST]). Five of the 12 published investigations in
this study utilized MedX software (v3.42; Sensor Sys-
tems, Inc., Sterling, VA), a semi-automated method
for segmentation and measurement with a heuristics-
based algorithm for volumetric analysis,14,15,17,18,21
while 5 of the 12 publications used a computerized
3D-volumetry method developed for WB-MRI using
the dynamic threshold level set method.10–12,16,19 There
are limited data with regards to characterization of
neoplasms as benign or malignant and no data to date
Table 1 Imaging parameters for WB-MRI from NF-related investigations focused on detection or characterization of PNST
Publication (see
references)
Technical considerations:
magnet strength
(1.5T vs 3T); sequences
(2D vs 3D); plane of acquisition
(axial, coronal, sagittal) Specific sequences Contrast material (1/2)
Functional DWI
and ADC mapping (1/2)
10 1.5T; 2D; coronal STIR 2 2
11 1.5T; 2Da STIR: slice thickness 5–10 mm;
matrix 256–512 3 256; T1; slice
thickness 5–10 mm; matrix
256–512 3 256
1; Gadolinium-DTPA (Magnevist,
Bayer Schering Pharma
AG, Germany)
2
12 1.5T; 2D; coronal STIR: TR/TE/IR 4,190/111/150;
echo train length 25; FOV 50 cm;
matrix 320 3 240; slice thickness
10 mm; no interslice gap
2 2
13 3.0T; 3D; coronal Pre and post contrast VIBE: TR/TE
0.88/2/43ms; FOV 50 cm2; matrix
256 3 256; slice thickness 2 mm;
STIR: TR/TE 6,640/84ms; FOV
50 cm2; matrix 256 3 256; slice
thickness 2 mm with interpolation
1; 0.1 mmol/kg gadodiamide
contrast agent (Magnevist,
Bayer Schering Pharma
AG, Germany)
1; TR/TE 4,100/70ms;
b values 50, 400,
800 s/mm2;
FOV 50 cm2; slice
thickness 5 mm
14 1.5T; 2D; coronal and axial STIR: axial; TR/TE 3,690 ms/106 ms;
FOV 25.7 3 50.0 cm; coronal; TR/TE
3,110 ms/101 ms; FOV 48 cm2; T1W
FS pre and post contrast: axial; TR/TE
91 ms/4.76 ms; FOV 47.9 cm2
0.1 mmol/kg or 0.2 mmol/kg
bodyweight gadolinium-DTPA
2
15 1.5T; 2Da STIR: slice thickness 10 mm;
no interslice gap
2 2
16 1.5T; 2D; coronal STIR: TR/TE/IR 4,190/111/150;
slice thickness 10 mm; no interslice
gap; FOV 50 cm2; echo train length
25; matrix 320 3 240
2 2
17 1.5T; 2D; axial STIR: slice thickness 10 mm 2 2
18 1.5T; 2D; axial STIR: slice thickness 10 mm 2 2
19 1.5T; 2D; coronal STIR: TR/TE/IR 4,190/111/150;
slice thickness 10 mm; no interslice
gap; FOV 50 cm2; echo train length
25; matrix 320 3 240
2 2
20 1.5T; 2D; coronal and axial Axial: T1 (slice thickness 6–12 mm);
T2 FS (slice thickness 6–12 mm);
coronal: T1 (slice thickness 5–10 mm);
T2 FS (slice thickness 5–10 mm)
2 2
21 1.5T; 2D; coronal and axial T1SE: slice thickness 5–10 mm;
no interslice gap; STIR; slice
thickness 5–10 mm; no interslice gap
2 2
Abbreviations: ADC 5 apparent diffusion coefficient; DWI 5 diffusion-weighted imaging; FOV 5 field of view; IR 5 inversion recovery; NF 5 neurofibro-
matosis; PNST 5 peripheral nerve sheath tumors; STIR 5 short tau inversion recovery; TE 5 echo time; TR 5 repetition time; VIBE 5 T1-weighted
sequences (volume interpolated breath-hold examination); WB-MRI 5 whole-body MRI.
a A plane of imaging is not specified.
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Table 2 Summary of WB-MRI investigations with respect to image interpretation focused on tumor detection (assessment of whole body
tumor burden), characterization, and treatment response
Reference
Patient population, n, sex composition
(% male), age, y Tumor detection (disease burden) Conclusion
10 245 total
PNST were segmented using computerized 3D-
volumetry methods developed for reference 19
Internal tumor burden is not a primary
contributor to QOL but it does
correlate with SF-36 bodily pain score
11 93 (31 NF1 with MPNST and 62 NF1 without MPNST),
58%, median age 34 (range 7–67)
PNST were segmented using computerized 3D-
volumetry methods developed for reference 19
Higher number of internal PNs and
a greater whole-body PN volume are
important risk factors for the
development of MPNST
12 19 (NF1), 52%, mean age 38 (range 19–58) Tumor volume range (0.4–1,182.4 mL); PNST
were segmented using computerized 3D-volumetry
methods developed for reference 19
NF1 patients with deep tumors and
tumors within the trunk are more likely to
have metabolically avid (SUVmax greater
than 2.5) PNST; increased PNST size,
location, and plexiform appearance were
associated with increased odds of having
a metabolically active PNST
13 11 (NF2 and SWN) 23 lesions (median 3.5 cm, range 1.0–10.2 cm);
2/23, cyst; 21/23, PNST
WB-MRI with volumetric sequences is
feasible for detection of PNST in NF;
addition of DWI and contrast enables
potential for characterization of cysts
vs tumors; cysts lack enhancement
and have higher ADC values
14 31, 42%, mean age 30.4 6 14.7 (range 2–63)
PNST were segmented using computerized 3D-
volumetry methods developed for reference 19
Although PET/CT has a higher
sensitivity on a per lesion basis for
characterization of PNST as benign or
malignant, addition of WB-MRI may
decrease the FP rate
15 201 (71 with internal PNST), 44%, median age
28.6 (range 1.7–63.4)
Volumetry was performed using MedX software
(v3.42; Sensor Systems, Sterling, VA), a heuristics-
based semi-automated method for segmentation
and measurement36
Whole-body PNST volume at the time
of the initial WB-MRI correlated with
the absolute rate of PNST growth; new
PNST are infrequent in patients with
NF1 with PNST and unlikely in patients
without PNST
16 247 Total of 1,286 PNST (528 plexiform and 758
circumscribed tumors); PNST volume, 65,423 mL
in 145/247 patients; PNST were segmented using
computerized 3D-volumetry methods developed
for reference 19
Patients with SWN had the highest
prevalence of PNST, but patients with
NF1 had the highest median tumor
volume
17 38 with large NF1 deletion and 114 age-
and sex-matched NF1 patients without large deletion
Internal PNST in 22/38 (58%) deletion and 67/114
(59%) nondeletion patients; volumetry was
performed using MedX software (v3.42; Sensor
Systems), a heuristics-based semi-automated
method for segmentation and measurement36
Patients with NF1 with large deletions
have higher internal PNST burden
18 65 (37 with PNST), 46%, mean 10.5
(range 1.7–17.6)
73 PNST; mean volume 145.5 mL (excluded PNST
, 3 cm); volumetry was performed using MedX
software (v3.42; Sensor Systems), a heuristics-
based semi-automated method for segmentation
and measurement36
PNST can cause clinical deficit in
pediatric patients with NF1
19 52 (NF1: 28, NF2: 14, SWN: 10), 48%,
mean age 42 6 15 (SD) (range 24–86)
398 Nerve sheath tumors (185 plexiform and 213
discrete tumors) were identified in 29 patients; manual
and semi-automated 3D segmented volumetry for
25 plexiform and 25 solitary PNST with high reliabilitya
DT level set semi-automated
segmentation is reliable relative to
manual segmentation
20 24 NF1, 29%, mean and median age 36
(range 15–59)
4/24, Plexiform; 20/24, solitary; no major problems
to differentiate PNST from lymph nodes, vessels, or cysts
WB-MRI is feasible in NF1 for detection
of PNST and assessment of tumor burden
21 39 (13 NF1 with MPNST and 2 age-/sex-matched
NF1 without MPNST), 46%
Volumetry using MEDx software platform37
WB-MRI enables detection of internal
PNST burden
Abbreviations: ADC5 apparent diffusion coefficient; DWI5 diffusion-weighted imaging; FP5 false positive; MPNST5malignant peripheral nerve sheath tumor;
NF1 5 neurofibromatosis type 1; NF2 5 neurofibromatosis type 2; PN 5 peripheral nerve; PNST 5 peripheral nerve sheath tumors; QOL 5 quality of life;
SF-36 5 Short Form–36; SWN 5 schwannomatosis; WB-MRI 5 whole-body MRI.
a Segmented using computerized 3D-volumetry methods developed for WB-MRI using (the dynamic threshold [DT] level set method).
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for assessment of treatment response, although such
analysis is ongoing in a clinical trial assessing WB-
MRI over time in people with NF2 treated with
bevacizumab (NCT01207687).
The data from tables 1 and 2 were critically evalu-
ated to generate knowledge gaps and future directions
for WB-MRI investigations to provide the required
metrics for inclusion of WB-MRI as a primary end-
point in clinical trials for NF-associated PNST. Priority
areas identified include WB-MRI reproducibility for
anatomical measures, optimal analysis techniques, and
establishing the minimal meaningful clinical difference
in tumor size (table 3).
DISCUSSION WB-MRI provides continuous cover-
age of lesions that cross anatomical boundaries and
therefore cannot be fully imaged with localized MRI,
a significant advantage when evaluating patients with
NF syndromes where there are frequently large infiltra-
tive tumors (figure) or multifocal PNST, which may be
missed without WB-MRI assessment.21 In this setting,
WB-MRI allows assessment of differential response
within and across tumors over time. An additional
advantage is that WB-MRI can be completed with
a typical scan time of 45–60 minutes on both 1.5T
and 3.0T systems and uses the same protocols for
patients of all ages, allowing continuity across and
within patients enrolled in a therapeutic trial.12,13,18
A major goal of this work was to identify core as-
pects of WB-MRI application for assessment of NF-
associated PNST to enable inclusion of WB-MRI as
a primary endpoint for therapeutic trials of NF-
associated PNST. There are no comparative data
available with respect to magnet strength, image
acquisition plane (axial vs coronal), 2D or 3D acqui-
sition, or the value of functional imaging and admin-
istration of contrast material available across all
available investigations. However, after the analyses
of the WB-MRI studies in patients with NF con-
ducted to date, several statements can be made:
WB-MRI in NF is feasible both at 1.5T or 3.0T; it
can be standardized across multiple sites for anatomic
tumor assessment in the setting of a clinical trial; both
2D and 3D acquisition are operational for generating
tumor data; STIR is a core sequence for evaluation of
tumor burden; and functional sequences such as
DWI can be considered in the setting of WB-MRI.
Outside of these statements, the WB-MRI Working
Group of REiNS is not able to make specific recom-
mendations for acquisition protocols at this time due
to a lack of data. For example, only a single case series
of 4 patients compared analysis of tumor burden in
patients with NF1 who underwent WB-MRI on both
1.5T and 3.0T within a 6-month period.24 This study
showed no difference in tumor volumes between the
2 magnet strengths; however, there are no other com-
parative analyses and this study is too small to draw
conclusions. The majority of studies completed to
date use 1.5T as this is more widely available. The
wide availability of 1.5T magnets is an advantage for
application of WB-MRI to multicenter trials. How-
ever, 3.0T WB-MRI has theoretical advantages, such
as increased signal to noise ratios (SNR), allowing for
improved 3D sequences as well as allowing for DWI
acquisition in an acceptable imaging time. Potential
disadvantages of 3.0T MRI include B1 field inhomo-
geneities and susceptibility artifacts.2,13 Work is ongo-
ing to optimize this with technological advances such as
continuous table motion and improved coils, which are
expected to shorten acquisition and increase SNR.2,25
With respect to specific sequences, the STIR
sequence, with its combined T1 and T2 weighting,
has been uniformly used in the WB-MRI investigations
for PNST. Most pathologic processes, including tu-
mors, are proton-rich with resultant prolonged T1
and T2 relaxation times and increased signal intensity
on STIR images. In addition, fat suppression is more
robust and homogeneous on inversion recovery sequen-
ces than other frequency selective sequences. These fea-
tures make the STIR sequence valuable for detection
and measurement of PNST and a core sequence for
assessment of whole body tumor burden in NF. How-
ever, detection of other pathologies in the viscera or the
skeletal system may require additional imaging.
Regarding 2D and 3D acquisitions, 11 of the 12
studies used 2D imaging sequences,10–12,14–21 while on-
ly 1 study (at 3.0T) obtained images with 3D volu-
metric sequences.13 This allows us to say that both are
feasible, but there are no data to suggest advantages of
one over the other. There are important differences in
spatial resolution between 2D and 3D sequences. For
2D sequences obtained at 1.5T, the in-plane resolution
can be 0.3–1.5 mm and the slice thickness can range
from 5 to 10 mm with no interslice gap. WB-MRI at
Table 3 Future directions for whole-body MRI (WB-MRI) investigations in
patients with neurofibromatosis (NF)
Sensitivity, specificity, and reproducibility of WB-MRI in NF
1. Comparative study of 3.0T vs 1.5T for tumor detection
2. Comparative study for 2D vs 3D acquisition for tumor detection
3. Comparative study of axial vs coronal imaging acquisition for tumor detection
4. Comparative study of regional vs WB-MRI for tumor detection
5. Test retest variability and interobserver performance of WB-MRI in NF
6. Determination of the minimally meaningful clinical change of tumor size with WB-MRI
Biologic characterization of tumor
1. Investigate functional MRI (diffusion-weighted imaging/apparent diffusion coefficient
mapping) vs other imaging modalities such as fluorodeoxyglucose PET for tumor
characterization and assessment of treatment response
2. Investigate the added value of contrast-enhanced imaging to WB-MRI protocol for
characterization and assessment of treatment response
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this resolution may not be adequate for the detection
or characterization of very small neoplasms and PNST
located in the skin and subcutaneous tissues. 3D
sequences obtained at 3.0T can have an interpolated
spatial resolution of 2 mmwith slice thickness of 2 mm
and no interslice gap.13 Both 2D and 3D sequences can
also be performed with higher spatial resolution, but at
the cost of longer acquisition time. A potential advan-
tage of 3D sequences includes MPR capabilities such
that a 3D isotropic dataset can be displayed in any
imaging plane. However, 3D acquisition may not be
available on all scanners, limiting application in mul-
ticenter studies.
For both 2D and 3D sequences, there is a lack of
consensus regarding an optimal imaging plane.
Although all WB-MRI investigations to date have
included the coronal plane, no comparative study
has been performed to determine the ideal imaging
plane. An advantage of coronal image acquisition is
that for anatomic sequences such as STIR or T1-
weigted imaging, there is less respiratory motion
due to faster image acquisition. Of note, the coronal
image acquisition may not be optimal for DWI, par-
ticularly in the neck and thoracic regions, due to car-
diac motion.
There is also a lack of data regarding the added
value of IV contrast material. Use of exogenous con-
trast requires venous access and hemodynamic mon-
itoring during the WB-MRI acquisition that may
reduce feasibility and carries the additional risk of
nephrogenic systemic fibrosis in the setting of renal
failure. New literature also suggests a relationship
between repetitive gadolinium exposure and high sig-
nal intensity in the basal ganglia, further raising con-
cern about exogenous contrast.26 There are currently
insufficient data to assess the potential diagnostic ben-
efit vs risk of the use of IV contrast for PNST. Finally,
no investigations have been performed to assess the
added value of DWI with ADC maps to standard
sequences in WB-MRI in patients with NF. This is
feasible and the potential advantages include the
assessment of tumor biology and possibly treatment
response, the ability to distinguish a cyst from a neo-
plasm, and the characterization of incidental findings.
For example, specific threshold ADC values enable
distinguishing soft tissue masses from cysts with high
specificity (100%), important when quantifying
tumor burden.13,27 Similarly, there is localized MRI
experience using DWI and ADC mapping for PNST
characterization as benign or malignant with 100%
sensitivity (95% confidence interval 66.4%–100%)
and 77% specificity.28 There is also limited experi-
ence comparing WB-MRI with whole body 18F-flu-
orodeoxyglucose (FDG) PET/CT for characterizing
PNST as benign or malignant.14 Although 18F-FDG
PET/CT had higher sensitivity (100%) compared
with WB-MRI (66.7%) on a per lesion basis, WB-
MRI had a higher specificity (97% for WB-MRI vs
74.4% for 18F-FDG PET/CT) for detecting malig-
nancy.14 WB-MRI in this particular investigation
used routine anatomic sequences only,14 and thus it
remains to be determined whether addition of quan-
titative functional MRI sequences with ADC meas-
urements would alter the diagnostic accuracy for
detection of malignancy.
Although WB-MRI with functional sequences for
detection and characterization of benign vs malignant
PNST shows promise, currently these sequences can
be difficult to perform uniformly across multiple sites.
No investigations have been published to date regard-
ing the assessment of treatment response in PNST in
NF, but there are efforts currently for analysis of
ongoing therapeutic studies with pretreatment and
posttreatment WB-MRI (NCT01207687). This
study will also allow assessment of the added value
of functional MRI or contrast-enhanced sequences
for assessing changes in tumor biology independent
of changes in tumor size.
With respect toWB-MRI analysis, the field has rec-
ommended volumetric measurements of tumor rather
than 2D measures.29–31 Tumor volumetry is preferred
for quantifying complex PNST such as plexiform neu-
rofibromas that can be large and infiltrative whereas
2D or linear measurement is more likely to misrepre-
sent the true tumor dimensions by overestimating or
underestimating PNST size and can be fraught with
interobserver and intraobserver variations.32–34 Tumor
volumetry, particularly in infiltrative plexiform neo-
plasms such as the ones identified in patients with
NF syndromes, has become the optimal approach for
assessing tumor burden. In addition, the current ther-
apeutic trials in NF syndromes use volumetric analysis
as a primary or secondary endpoint (NCT01362803,
NCT02101736, NCT02096471). Volumetric tumor
burden can be measured manually, though this is time-
consuming and impractical for routine clinical evalua-
tion. Computer-aided tumor segmentation of PNST
can be performed on MRI sequences that show clear
distinction between tumor and surrounding normal
tissue, such as STIR or similar fluid sensitive sequen-
ces. In one study comparing manual and semi-
automated tumor volumetry, computerized volumetry
using a dynamic threshold method was superior to
manual segmentation techniques.19 Moreover, com-
puterized volumetry was reliable and less labor inten-
sive, which made it more repeatable compared to
manual segmentation.19 It is important to note that
reliability and repeatability were calculated using a small
sample size19; however, this technique has subse-
quently been applied in larger studies of approximately
250 patients.10–12 A multicenter study comparing the 2
principal semi-automated methods for reliability and
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interpretation time compared with the manual tech-
nique in lesion detection and change in lesion size is
currently underway.
Although there are several advantages to WB-MRI
for NF, there are also important limitations. First, for
very tall or large individuals, portions of the body may
not be adequately imaged, including the distal legs,
shoulders, and arms. Adequate imaging of the distal
lower extremities is a particular concern for 3.0T
scanners and may limit the use of WB-MRI if there
are tumors of interest in these regions. This can be ad-
dressed by imaging the upper and lower body sepa-
rately; however, this increases cost and time. An
additional concern for tumor assessment with WB-
MRI is that the lower limit of tumor volume that
can be assessed has not been described, and depend-
ing on the WB-MRI technique as well as the tumor
distribution, the cutoff value may be variable. Select-
ing the same PNST for contouring consistently over
consecutive scans is crucial for determining size
change and can only be done on comparable quality
image sets. Similarly, diagnostic performance of
WB-MRI for total tumor burden estimates is depen-
dent on the correct representation of the body on the
MRI and needs to be standardized across sites and
time points. Importantly, WB-MRI can suffer from
varied image distortions at the periphery of the imag-
ing field, which may lead to measurement errors.13
Given spatial resolution limitations and depending
on what sequences are applied, additional dedicated
MRI sequences such as magnetic resonance neurog-
raphy may be necessary to provide improved ana-
tomic and functional characterization of PNST,35
evaluate tumors in and around the spinal cord, iden-
tify small tumors such as pheochromocytomas, or
diagnose vascular anomalies. Finally, it is worth not-
ing that there are some limitations to the analysis
presented based on the very limited literature on this
topic. Only 14 investigations fulfilled search criteria.
Of these, several studies had overlapping patient data
and WB-MRI protocols reported with separate end-
points.10,16,19 This further highlights the need for
additional research on WB-MRI performance in
NF syndromes (table 3).
Choosing standardized image acquisition and
analysis methods is essential for optimal multicenter
collaboration applying WB-MRI as a tool for assess-
ing tumors in NF. WB-MRI may serve as either a pri-
mary or secondary endpoint in clinical drug trials that
target multiple tumors requiring systemic rather than
localized imaging. The systematic process developed
by the REiNSWB-MRIWorking Group has enabled
a multicenter conversation about imaging protocols
and the development of future comparative projects.
These results will be used by the group to identify
the most appropriate WB-MRI acquisition and
interpretation methods for individuals with NF syn-
dromes in future clinical trials and prioritize research
questions about the optimal use of WB-MRI as an
endpoint measure in NF research.
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